You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020142015
Dec 202036015
Jan 20211405
Feb 20211604
Mar 20218004
Apr 20214607
May 20211101
Jun 20210011
Jul 2021008
Aug 2021004
Sep 2021007
Oct 202112014
Nov 202126013
Dec 20213004
Jan 20221401
Feb 20222402
Mar 2022401
Apr 20222606
May 20222800
Jun 20226000
Jul 20222606
Aug 20223404
Sep 20222200
Oct 20222002
Nov 2022801
Dec 20221400
Jan 20231001
Feb 20232200
Mar 20231802
Apr 20231802
May 2023400
Jun 20231201
Jul 20231002
Aug 2023601
Sep 20231000
Oct 20233004
Nov 20232201
Dec 20233800
Jan 20242000
Feb 20241400
Mar 20242801
Apr 20241602
May 20242000
Jun 20241000
Jul 20242202
Aug 20242403
Sep 2024801
Oct 20241203
Nov 20241404
Dec 20241605
Jan 20251207
Feb 2025202
Mar 2025001
Apr 2025003
May 2025003
Jun 2025003
Total11110189